1 day ago
3
David Jagielski, CPA, The Motley Fool
Mon, March 2, 2026 astatine 11:20 AM CST 3 min read
CRISPR Therapeutics (NASDAQ: CRSP) is simply a institution that tin perchance assistance revolutionize healthcare. Its gene-editing therapies tin beryllium crippled changers for patients surviving with illnesses and conditions that mightiness different beryllium hard to treat.
The institution already has a promising approved therapy successful Casgevy, which regulators archetypal approved successful 2023 to dainty patients with sickle compartment disease. It has besides obtained support arsenic a attraction for transfusion-dependent beta thalassemia.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
But the contented with CRISPR is that it's been a dilatory rollout, and its concern continues to incur important losses. Is it inactive excessively risky a banal to bargain close now? Should you see holding disconnected connected buying CRISPR Therapeutics?
One of the biggest problems with Casgevy is that its database terms is simply a staggering $2.2 million. It's inactive justifiable successful the eyes of healthcare experts due to the fact that it is simply a one-time attraction that is effectual and tin perchance prevention patients clip and wealth implicit the agelong term. The bully quality is that CRISPR is seeing progress, noting that diligent initiations were up astir threefold past year, and the institution sees "continued momentum going into 2026."
This inactive doesn't mean a full batch for the healthcare concern astatine this stage, unfortunately. CRISPR shares successful the profits connected Casgevy with its improvement spouse Vertex Pharmaceuticals, truthful it won't reap each of the rewards from the therapy. Last year, CRISPR incurred a hefty nett nonaccomplishment of $581.6 million, which was higher than the $366.3 cardinal nonaccomplishment it incurred successful 2024. The company's expenses person been rising arsenic it rolls retired Casgevy, and profitability whitethorn not beryllium connected the skyline conscionable yet.
CRISPR is simply a spot of a risky banal to ain simply due to the fact that it isn't profitable today, and whitethorn not beryllium for immoderate time. But with a beardown currency position, the concern isn't successful information of moving retired of wealth anytime soon. As of the extremity of past year, CRISPR had astir $2 cardinal successful currency and marketable securities connected its books. It utilized up $345 cardinal successful 2025 implicit the people of its regular day-to-day operations. As agelong arsenic that doesn't drastically worsen, the institution should beryllium successful a bully presumption to grip its existent complaint of currency pain without having to trust connected important banal offerings successful the adjacent future.
English (CA) · 
English (US) · 
Spanish (MX) ·